S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
US Dollar Replaced By "Biden Bucks"? (Ad)
OTCMKTS:HYPMY

Hypera - HYPMY Stock Forecast, Price & News

$8.31
+0.26 (+3.23%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.22
$8.33
50-Day Range
$6.86
$8.72
52-Week Range
$4.63
$8.89
Volume
8,456 shs
Average Volume
15,482 shs
Market Capitalization
$5.26 billion
P/E Ratio
19.95
Dividend Yield
1.99%
Price Target
N/A
HYPMY stock logo

About Hypera (OTCMKTS:HYPMY) Stock

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex - A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.

Receive HYPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.

HYPMY Stock News Headlines

Hypera SA ADR - Stock Quote HYPMY
Hypera S/A ADR
Brazil's Hypera to sell Xantinon drug to Uniao Quimica
Brazilian drugmaker Hypera cuts 2020 revenue outlook
A Potentially Overlooked Trio to Consider
HYPMY.PQ - Hypera SA Profile | Reuters
See More Headlines
Receive HYPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.

HYPMY Company Calendar

Today
8/12/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HYPMY
Fax
N/A
Employees
8,918
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$793.81 million
Cash Flow
$0.44 per share
Book Value
$2.83 per share

Miscellaneous

Free Float
N/A
Market Cap
$5.26 billion
Optionable
Not Optionable
Beta
0.82

Key Executives

  • Mr. Breno Toledo Pires de Oliveira
    Chief Exec. Officer
  • Mr. Adalmario Ghovatto Satheler do Couto
    Investor Relations Officer & CFO
  • Mr. Carlos Roberto Scorsi (Age 60)
    Chief Operating officer
  • Juliana Aguinaga Damião Salem
    Chief Legal & Compliance Officer
  • Mr. Luiz Eduardo Sales Clavis
    Commercial & Marketing VP
  • Mr. Nelson José de Mello (Age 63)
    Chief Corp. Relations Officer
  • Mr. Hélio Segouras
    Head of Consumer Health
  • Mr. Claudio Bergamo dos Santos (Age 57)
    Pres of Pharma & Director
  • Mr. Martim Prado Mattos (Age 42)
    Sec.
  • Mr. Luiz Eduardo Violland
    Chief Exec. Officer of the Pharmaceutical Division













HYPMY Stock - Frequently Asked Questions

How have HYPMY shares performed in 2022?

Hypera's stock was trading at $5.00 on January 1st, 2022. Since then, HYPMY stock has increased by 66.2% and is now trading at $8.31.
View the best growth stocks for 2022 here
.

Are investors shorting Hypera?

Hypera saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 3,600 shares, an increase of 350.0% from the June 30th total of 800 shares. Based on an average daily volume of 25,800 shares, the days-to-cover ratio is currently 0.1 days.
View Hypera's Short Interest
.

Is Hypera a good dividend stock?

Hypera (OTCMKTS:HYPMY) pays an annual dividend of $0.16 per share and currently has a dividend yield of 1.99%.
Read our dividend analysis for HYPMY.

What is Hypera's stock symbol?

Hypera trades on the OTCMKTS under the ticker symbol "HYPMY."

How do I buy shares of Hypera?

Shares of HYPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hypera's stock price today?

One share of HYPMY stock can currently be purchased for approximately $8.31.

How much money does Hypera make?

Hypera (OTCMKTS:HYPMY) has a market capitalization of $5.26 billion and generates $793.81 million in revenue each year.

How many employees does Hypera have?

The company employs 8,918 workers across the globe.

How can I contact Hypera?

Hypera's mailing address is AV. MAGALHAES DE CASTRO 4800 - 24¿ ANDAR EDIFICIO CONTINENTAL TOWER, SAO PAULO D5, 05676-120. The official website for the company is www.hyperapharma.com.br. The company can be reached via phone at 55-11-3627-4206 or via email at ir@hypera.com.

This page (OTCMKTS:HYPMY) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.